TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Benzinga Logo Benzinga By Vandana Singh
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron reported Q3 earnings of $11.83 per share, beating expectations, with sales of $3.75 billion. Eylea sales decreased due to competitive pressures, while Dupixent sales and Sanofi collaboration revenue showed strength.

Insights
MSpF   positive

Highlighted as showing strong earnings across the economy


REGN   neutral

Mixed performance with earnings beating expectations but Eylea sales declining and receiving a Complete Response Letter from FDA